⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 17, 2025

Supplemental Fig S8 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Funda Meric‐Bernstam Martin Gutierrez Enrique Sanz‐García Diego Villa Jun Zhang Jennifer Friedmann Fengting Yan Mark A. Socinski John Sarantopoulos Luis E. Raez Quincy S. Chu Maxime Chénard-Poirier Manash S. Chatterjee Hong Ren Qi Liu Douglas A. Levine Komal Jhaveri

View at Publisher

Ask AI

Bookmark

Share

Key Points

Zilovertamab vedotin showed a distinct plasma concentration profile over time in participants.
The study utilized intravenous administration every three weeks to assess total antibody pharmacokinetics.
Phase 2 design allowed for detailed examination of drug behavior in a targeted patient population.
These findings may impact future treatment strategies for metastatic solid tumors.

Implication

Phase 2 study evaluates plasma concentration over time in participants with metastatic solid tumors, suggesting effective dosing.

Abstract

Supplemental Fig S8. Plasma Conc. vs Time Profiles of Total AB in C1 Following Zilovertamab Vedotin IV Twice Every 3 Wks

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meric‐Bernstam et al. (2025) studied this question.

synapsesocial.com/papers/68d462b631b076d99fa61afa https://doi.org/10.1158/2767-9764.30146502

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Fig S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
2Supplemental Fig S9 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
3Supplemental Fig S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
4Supplemental Fig S10 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
5Supplemental Fig S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025

More related papers

Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025